BiotechTube

Duloxetine + venlafaxine + placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anxiety Disorder

Conditions

Anxiety Disorder

Trial Timeline

Apr 1, 2005 → Jan 1, 2007

NCT ID
NCT00122837

About Duloxetine + venlafaxine + placebo

Duloxetine + venlafaxine + placebo is a phase 3 stage product being developed by Eli Lilly for Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00122837. Target conditions include Anxiety Disorder.

What happened to similar drugs?

19 of 20 similar drugs in Anxiety Disorder were approved

Approved (19) Terminated (2) Active (1)
✅Duloxetine + PlaceboEli LillyApproved
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
✅Cariprazine + PlaceboAbbVieApproved
✅EscitalopramAbbVieApproved
✅QuetiapineAstraZenecaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅QuetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00122837Phase 3Completed
NCT00122850Phase 3Completed

Competing Products

20 competing products in Anxiety Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine + venlafaxine + placeboEli LillyPhase 3
40
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyApproved
43
Duloxetine Hydrochloride + placeboEli LillyPhase 3
40
duloxetine + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
43
risperidone oral tabletsJohnson & JohnsonPhase 3
40
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
27
ABBV-932 + PlaceboAbbViePhase 1
29
Cariprazine + PlaceboAbbVieApproved
43
EscitalopramAbbVieApproved
43
QuetiapineAstraZenecaApproved
43
Quetiapine extended release tablet + PlaceboAstraZenecaApproved
43
AZD7325 + Radioligand (11C) flumazenilAstraZenecaPhase 1
29
AZD7325 + AZD7325 + AZD7325 + PlaceboAstraZenecaPhase 2
35